Skip to main content
Erschienen in: Angiogenesis 1/2014

01.01.2014 | Original Paper

Isolation of human lymphatic malformation endothelial cells, their in vitro characterization and in vivo survival in a mouse xenograft model

verfasst von: Zerina Lokmic, Geraldine M. Mitchell, Nicholas Koh Wee Chong, Jacqueline Bastiaanse, Yi-Wen Gerrand, Yiping Zeng, Elizabeth D. Williams, Anthony J. Penington

Erschienen in: Angiogenesis | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Human lymphatic vascular malformations (LMs), also known as cystic hygromas or lymphangioma, consist of multiple lymphatic endothelial cell-lined lymph-containing cysts. No animal model of this disease exists. To develop a mouse xenograft model of human LM, CD34NegCD31Pos LM lymphatic endothelial cells (LM-LEC) were isolated from surgical specimens and compared to foreskin CD34NegCD31Pos lymphatic endothelial cells (LECs). Cells were implanted into a mouse tissue engineering model for 1, 2 and 4 weeks. In vitro LM-LECs showed increased proliferation and survival under starvation conditions (P < 0.0005 at 48 h, two-way ANOVA), increased migration (P < 0.001, two-way ANOVA) and formed fewer (P = 0.029, independent samples t test), shorter tubes (P = 0.029, independent samples t test) than foreskin LECs. In vivo LM-LECs implanted into a Matrigel™-containing mouse chamber model assembled to develop vessels with dilated cystic lumens lined with flat endothelium, morphology similar to that of clinical LMs. Human foreskin LECs failed to survive implantation. In LM-LEC implanted chambers the percent volume of podoplaninPos vessels was 1.18 ± 2.24 % at 1 week, 6.34 ± 2.68 % at 2 weeks and increasing to 7.67 ± 3.60 % at 4 weeks. In conclusion, the significantly increased proliferation, migration, resistance to apoptosis and decreased tubulogenesis of LM-LECs observed in vitro is likely to account for their survival and assembly into stable LM-like structures when implanted into a mouse vascularised chamber model. This in vivo xenograft model will provide the basis of future studies of LM biology and testing of potential pharmacological interventions for patients with lymphatic malformations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Brice G, Child AH, Evans A, Bell R, Mansour S, Burnand K, Sarfarazi M, Jeffery S, Mortimer P (2005) Milroy disease and the VEGFR-3 mutation phenotype. J Med Genet 42:98–102PubMedCrossRef Brice G, Child AH, Evans A, Bell R, Mansour S, Burnand K, Sarfarazi M, Jeffery S, Mortimer P (2005) Milroy disease and the VEGFR-3 mutation phenotype. J Med Genet 42:98–102PubMedCrossRef
2.
Zurück zum Zitat Nakamura K, Rockson SG (2007) Biomarkers of lymphatic function and disease: state of the art and future directions. Mol Diagn Ther 11:227–238PubMedCrossRef Nakamura K, Rockson SG (2007) Biomarkers of lymphatic function and disease: state of the art and future directions. Mol Diagn Ther 11:227–238PubMedCrossRef
3.
Zurück zum Zitat Castro EC, Galambos C (2009) Prox-1 and VEGFR3 antibodies are superior to D2-40 in identifying endothelial cells of lymphatic malformations-a proposal of a new immunohistochemical panel to differentiate lymphatic from other vascular malformations. Pediatr Dev Pathol 12:187–194PubMedCrossRef Castro EC, Galambos C (2009) Prox-1 and VEGFR3 antibodies are superior to D2-40 in identifying endothelial cells of lymphatic malformations-a proposal of a new immunohistochemical panel to differentiate lymphatic from other vascular malformations. Pediatr Dev Pathol 12:187–194PubMedCrossRef
4.
Zurück zum Zitat Filston HC (1994) Hemangiomas, cystic hygromas, and teratomas of the head and neck. Semin Pediatr Surg 3:147–159PubMed Filston HC (1994) Hemangiomas, cystic hygromas, and teratomas of the head and neck. Semin Pediatr Surg 3:147–159PubMed
5.
Zurück zum Zitat Rottem S, Bronshtein M (1990) Transvaginal sonographic diagnosis of congenital anomalies between 9 weeks and 16 weeks menstrual age. J Clin Ultrasound 18:307–314PubMedCrossRef Rottem S, Bronshtein M (1990) Transvaginal sonographic diagnosis of congenital anomalies between 9 weeks and 16 weeks menstrual age. J Clin Ultrasound 18:307–314PubMedCrossRef
6.
Zurück zum Zitat Puig S, Casati B, Staudenherz A, Paya K (2005) Vascular low-flow malformations in children: current concepts for classification, diagnosis and therapy. Eur J Radiol 53:35–45PubMedCrossRef Puig S, Casati B, Staudenherz A, Paya K (2005) Vascular low-flow malformations in children: current concepts for classification, diagnosis and therapy. Eur J Radiol 53:35–45PubMedCrossRef
7.
Zurück zum Zitat Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69:412–422PubMedCrossRef Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69:412–422PubMedCrossRef
8.
Zurück zum Zitat Enjolras O, Wassef M, Chapot R (2007) Colour atlas of vascular tumours and vascular malformations. Cambridge University Press, New YorkCrossRef Enjolras O, Wassef M, Chapot R (2007) Colour atlas of vascular tumours and vascular malformations. Cambridge University Press, New YorkCrossRef
9.
Zurück zum Zitat Vikkula M, Boon LM, Mulliken JB, Olsen BR (1998) Molecular basis of vascular anomalies. Trends Cardiovasc Med 8:281–292PubMedCrossRef Vikkula M, Boon LM, Mulliken JB, Olsen BR (1998) Molecular basis of vascular anomalies. Trends Cardiovasc Med 8:281–292PubMedCrossRef
10.
Zurück zum Zitat Padwa BL, Hayward PG, Ferraro NF, Mulliken JB (1995) Cervicofacial lymphatic malformation: clinical course, surgical intervention, and pathogenesis of skeletal hypertrophy. Plast Reconstr Surg 95:951–960PubMedCrossRef Padwa BL, Hayward PG, Ferraro NF, Mulliken JB (1995) Cervicofacial lymphatic malformation: clinical course, surgical intervention, and pathogenesis of skeletal hypertrophy. Plast Reconstr Surg 95:951–960PubMedCrossRef
11.
12.
Zurück zum Zitat Mulliken JB, Glowacki J (1982) Classification of pediatric vascular lesions. Plast Reconstr Surg 70:120–121PubMedCrossRef Mulliken JB, Glowacki J (1982) Classification of pediatric vascular lesions. Plast Reconstr Surg 70:120–121PubMedCrossRef
13.
Zurück zum Zitat Galambos C, Nodit L (2005) Identification of lymphatic endothelium in pediatric vascular tumors and malformations. Pediatr Dev Pathol 8:181–189PubMedCrossRef Galambos C, Nodit L (2005) Identification of lymphatic endothelium in pediatric vascular tumors and malformations. Pediatr Dev Pathol 8:181–189PubMedCrossRef
14.
Zurück zum Zitat Edwards PD, Rahbar R, Ferraro NF, Burrows PE, Mulliken JB (2005) Lymphatic malformation of the lingual base and oral floor. Plast Reconstr Surg 115:1906–1915PubMedCrossRef Edwards PD, Rahbar R, Ferraro NF, Burrows PE, Mulliken JB (2005) Lymphatic malformation of the lingual base and oral floor. Plast Reconstr Surg 115:1906–1915PubMedCrossRef
15.
Zurück zum Zitat Brouillard P, Vikkula M (2003) Vascular malformations: localized defects in vascular morphogenesis. Clin Genet 63:340–351PubMedCrossRef Brouillard P, Vikkula M (2003) Vascular malformations: localized defects in vascular morphogenesis. Clin Genet 63:340–351PubMedCrossRef
16.
Zurück zum Zitat Huang H-Y, Ho C-C, Huang P-H, Hsu S-M (2001) Co-Expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. Lab Invest 81:1729–1734PubMedCrossRef Huang H-Y, Ho C-C, Huang P-H, Hsu S-M (2001) Co-Expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. Lab Invest 81:1729–1734PubMedCrossRef
17.
Zurück zum Zitat Jackson IT, Carreno R, Potparic Z, Hussain K (1993) Hemangiomas, vascular malformations, and lymphovenous malformations: classification and methods of treatment. Plast Reconstr Surg 91:1216–1230PubMedCrossRef Jackson IT, Carreno R, Potparic Z, Hussain K (1993) Hemangiomas, vascular malformations, and lymphovenous malformations: classification and methods of treatment. Plast Reconstr Surg 91:1216–1230PubMedCrossRef
19.
Zurück zum Zitat Lokmic Z, Mitchell GM (2008) Engineering the microcirculation. Tissue Eng Part B Rev 14:87–103PubMedCrossRef Lokmic Z, Mitchell GM (2008) Engineering the microcirculation. Tissue Eng Part B Rev 14:87–103PubMedCrossRef
20.
Zurück zum Zitat Cronin KJ, Messina A, Knight KR, Cooper-White JJ, Stevens GW, Penington AJ, Morrison WA (2004) New murine model of spontaneous autologous tissue engineering, combining an arteriovenous pedicle with matrix materials. Plast Reconstr Surg 113:260–269PubMedCrossRef Cronin KJ, Messina A, Knight KR, Cooper-White JJ, Stevens GW, Penington AJ, Morrison WA (2004) New murine model of spontaneous autologous tissue engineering, combining an arteriovenous pedicle with matrix materials. Plast Reconstr Surg 113:260–269PubMedCrossRef
21.
Zurück zum Zitat Tilkorn DJ, Davies EM, Keramidaris E, Dingle AM, Gerrand Y-W, Taylor CJ, Han X-L, Palmer JA, Penington AJ, Mitchell CA, Morrison WA, Dusting GJ, Mitchell GM (2012) The in vitro preconditioning of myoblasts to enhance subsequent survival in an in vivo tissue engineering chamber model. Biomaterials 33:3868–3879PubMedCrossRef Tilkorn DJ, Davies EM, Keramidaris E, Dingle AM, Gerrand Y-W, Taylor CJ, Han X-L, Palmer JA, Penington AJ, Mitchell CA, Morrison WA, Dusting GJ, Mitchell GM (2012) The in vitro preconditioning of myoblasts to enhance subsequent survival in an in vivo tissue engineering chamber model. Biomaterials 33:3868–3879PubMedCrossRef
22.
Zurück zum Zitat Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:946–953PubMedCrossRef Alitalo K, Tammela T, Petrova TV (2005) Lymphangiogenesis in development and human disease. Nature 438:946–953PubMedCrossRef
23.
Zurück zum Zitat Zeng Y, Opeskin K, Horvath LG, Sutherland RL, Williams ED (2005) Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 65:222–230PubMedCrossRef Zeng Y, Opeskin K, Horvath LG, Sutherland RL, Williams ED (2005) Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 65:222–230PubMedCrossRef
24.
Zurück zum Zitat Zeng Y, Wang F, Williams ED, Chow CW (2005) Lymphatics in the alimentary tract of children in health and disease: study on mucosal biopsies using the monoclonal antibody d2-40. Pediatr Dev Pathol 8:541–549PubMedCrossRef Zeng Y, Wang F, Williams ED, Chow CW (2005) Lymphatics in the alimentary tract of children in health and disease: study on mucosal biopsies using the monoclonal antibody d2-40. Pediatr Dev Pathol 8:541–549PubMedCrossRef
25.
Zurück zum Zitat Zeng Y, Opeskin K, Goad J, Williams ED (2006) Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 66:9566–9575PubMedCrossRef Zeng Y, Opeskin K, Goad J, Williams ED (2006) Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. Cancer Res 66:9566–9575PubMedCrossRef
27.
Zurück zum Zitat Louis KS, Siegel AC (2011) Cell viability analysis using trypan blue: manual and automated methods. Methods Mol Biol 740:7–12 Louis KS, Siegel AC (2011) Cell viability analysis using trypan blue: manual and automated methods. Methods Mol Biol 740:7–12
28.
Zurück zum Zitat Howard CV, Reed MG (2005) Unbiased stereology. BIOS Scientific Publishers, Taylor & Francis Group, Oxon Howard CV, Reed MG (2005) Unbiased stereology. BIOS Scientific Publishers, Taylor & Francis Group, Oxon
29.
Zurück zum Zitat Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rössler J (2002) The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. FASEB J 16:1271–1273PubMed Wilting J, Papoutsi M, Christ B, Nicolaides KH, von Kaisenberg CS, Borges J, Stark GB, Alitalo K, Tomarev SI, Niemeyer C, Rössler J (2002) The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. FASEB J 16:1271–1273PubMed
30.
Zurück zum Zitat Corselli M, Chen CW, Sun B, Yap S, Rubin JP, Peault B (2012) The tunica adventitia of human arteries and veins as a source of mesenchymal stem cells. Stem Cells Dev 21:1299–1308PubMedCrossRef Corselli M, Chen CW, Sun B, Yap S, Rubin JP, Peault B (2012) The tunica adventitia of human arteries and veins as a source of mesenchymal stem cells. Stem Cells Dev 21:1299–1308PubMedCrossRef
31.
Zurück zum Zitat Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL (2012) Sildenafil for severe lymphatic malformations. N Engl J Med 366:384–386PubMedCrossRef Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL (2012) Sildenafil for severe lymphatic malformations. N Engl J Med 366:384–386PubMedCrossRef
32.
Zurück zum Zitat Dai Y, Hou F, Saad A, Fan CY, Buckmiller LM, Suen JY, Richter GT (2011) Preliminary investigation of human lymphatic malformations in vitro. Laryngoscope 121:2435–2442PubMedCrossRef Dai Y, Hou F, Saad A, Fan CY, Buckmiller LM, Suen JY, Richter GT (2011) Preliminary investigation of human lymphatic malformations in vitro. Laryngoscope 121:2435–2442PubMedCrossRef
33.
Zurück zum Zitat Sun Y, Jia J, Zhang W, Liu B, Zhang Z, Zhao Y (2011) A reproducible in vivo model of lymphatic malformation in rats. J Comp Pathol 145:390–398PubMedCrossRef Sun Y, Jia J, Zhang W, Liu B, Zhang Z, Zhao Y (2011) A reproducible in vivo model of lymphatic malformation in rats. J Comp Pathol 145:390–398PubMedCrossRef
34.
Zurück zum Zitat Bennett G, April M, Huvos AG (2004) Lymphatic malformation of the sphenoid sinus in a pediatric patient. Otolaryngol Head Neck Surg 131:784–786PubMedCrossRef Bennett G, April M, Huvos AG (2004) Lymphatic malformation of the sphenoid sinus in a pediatric patient. Otolaryngol Head Neck Surg 131:784–786PubMedCrossRef
35.
Zurück zum Zitat Zhang XD, Gillespie SK, Hersey P (2004) Staurosporine induces apoptosis of melanoma by both caspase-dependent and caspase-independent apoptotic pathways. Mol Cancer Ther 2004(3):187–197 Zhang XD, Gillespie SK, Hersey P (2004) Staurosporine induces apoptosis of melanoma by both caspase-dependent and caspase-independent apoptotic pathways. Mol Cancer Ther 2004(3):187–197
36.
Zurück zum Zitat Cavallaro U, Dejana E (2011) Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol 12:189–197 Cavallaro U, Dejana E (2011) Adhesion molecule signalling: not always a sticky business. Nat Rev Mol Cell Biol 12:189–197
37.
Zurück zum Zitat Dejana E (2004) Endothelial cell–cell junctions: happy together. Nat Rev Mol Cell Biol 5:261–270PubMedCrossRef Dejana E (2004) Endothelial cell–cell junctions: happy together. Nat Rev Mol Cell Biol 5:261–270PubMedCrossRef
38.
Zurück zum Zitat Raymond MA, Vigneault N, Luyckx V, Hebert MJ (2002) Paracrine repercussions of preconditioning on angiogenesis and apoptosis of endothelial cells. Biochem Biophys Res Commun 291:261–269PubMedCrossRef Raymond MA, Vigneault N, Luyckx V, Hebert MJ (2002) Paracrine repercussions of preconditioning on angiogenesis and apoptosis of endothelial cells. Biochem Biophys Res Commun 291:261–269PubMedCrossRef
39.
Zurück zum Zitat Wautier MP, Boval B, Chappey O, Enjolras O, Wernert N, Merland JJ, Wautier JL (1999) Cultured endothelial cells from human arteriovenous malformations have defective growth regulation. Blood 94:2020–2028PubMed Wautier MP, Boval B, Chappey O, Enjolras O, Wernert N, Merland JJ, Wautier JL (1999) Cultured endothelial cells from human arteriovenous malformations have defective growth regulation. Blood 94:2020–2028PubMed
40.
41.
Zurück zum Zitat Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, Klein R, Wilkinson GA (2005) PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19:397–410PubMedCrossRef Makinen T, Adams RH, Bailey J, Lu Q, Ziemiecki A, Alitalo K, Klein R, Wilkinson GA (2005) PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev 19:397–410PubMedCrossRef
42.
43.
Zurück zum Zitat Mikhaylova M, Mori N, Wildes FB, Walczak P, Gimi B, Bhujwalla ZM (2008) Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia 10:380–389PubMedCentralPubMed Mikhaylova M, Mori N, Wildes FB, Walczak P, Gimi B, Bhujwalla ZM (2008) Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia 10:380–389PubMedCentralPubMed
44.
Zurück zum Zitat Garaffa E, Caprara V, Di Castro V, Rosano L, Bagnato A, Spinella F (2012) Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factors -C, -D and -A in lymphatic endothelial cells. Life Sci 19:638–643CrossRef Garaffa E, Caprara V, Di Castro V, Rosano L, Bagnato A, Spinella F (2012) Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factors -C, -D and -A in lymphatic endothelial cells. Life Sci 19:638–643CrossRef
45.
Zurück zum Zitat Irigoyen M, Anso E, Martinez E, Garoya M, Martinez-Irujo JJ, Rouzant A (2007) Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 1773:880–890PubMedCrossRef Irigoyen M, Anso E, Martinez E, Garoya M, Martinez-Irujo JJ, Rouzant A (2007) Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 1773:880–890PubMedCrossRef
46.
47.
48.
Zurück zum Zitat Norgall S, Papoutsi M, Rossler J, Schweigerer L, Wilting J, Weich HA (2007) Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. BMC Cancer 7:105–122PubMedCentralPubMedCrossRef Norgall S, Papoutsi M, Rossler J, Schweigerer L, Wilting J, Weich HA (2007) Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. BMC Cancer 7:105–122PubMedCentralPubMedCrossRef
49.
Zurück zum Zitat Stacker S, Hughes R, Williams R, Achen M (2006) Current strategies for modulating lymphangiogenesis signalling pathways in human disease. Curr Med Chem 13:783–792PubMedCrossRef Stacker S, Hughes R, Williams R, Achen M (2006) Current strategies for modulating lymphangiogenesis signalling pathways in human disease. Curr Med Chem 13:783–792PubMedCrossRef
50.
Zurück zum Zitat Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L (2003) Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 278:40973–40979PubMedCrossRef Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K, Claesson-Welsh L (2003) Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 278:40973–40979PubMedCrossRef
Metadaten
Titel
Isolation of human lymphatic malformation endothelial cells, their in vitro characterization and in vivo survival in a mouse xenograft model
verfasst von
Zerina Lokmic
Geraldine M. Mitchell
Nicholas Koh Wee Chong
Jacqueline Bastiaanse
Yi-Wen Gerrand
Yiping Zeng
Elizabeth D. Williams
Anthony J. Penington
Publikationsdatum
01.01.2014
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 1/2014
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-013-9371-8

Weitere Artikel der Ausgabe 1/2014

Angiogenesis 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.